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Defective immuno- and 
thymoproteasome assembly causes 
severe immunodeficiency
Irina Treise1,3,11, Eva M. Huber2, Tanja Klein-Rodewald3,7, Wolfgang Heinemeyer2, Simon 
A. Grassmann1, Michael Basler  8, Thure Adler1,3,11, Birgit Rathkolb3,4,13, Laura Helming1, 
Christian Andres9, Matthias Klaften3, Christina Landbrecht4, Thomas Wieland6, Tim M. Strom6,16, 
Kathy D. McCoy5, Andrew J. Macpherson5, Eckhard Wolf  4, Marcus Groettrup8, Markus Ollert14,15, 
Frauke Neff3,7, Valerie Gailus-Durner3, Helmut Fuchs  3, Martin Hrabě de Angelis  3,12,13, 
Michael Groll2 & Dirk H. Busch  1,10,11
By N-ethyl-N-nitrosourea (ENU) mutagenesis, we generated the mutant mouse line TUB6 that is 
characterised by severe combined immunodeficiency (SCID) and systemic sterile autoinflammation 
in homozygotes, and a selective T cell defect in heterozygotes. The causative missense point 
mutation results in the single amino acid exchange G170W in multicatalytic endopeptidase complex 
subunit-1 (MECL-1), the β2i-subunit of the immuno- and thymoproteasome. Yeast mutagenesis and 
crystallographic data suggest that the severe TUB6-phenotype compared to the MECL-1 knockout 
mouse is caused by structural changes in the C-terminal appendage of β2i that prevent the biogenesis 
of immuno- and thymoproteasomes. Proteasomes are essential for cell survival, and defective 
proteasome assembly causes selective death of cells expressing the mutant MECL-1, leading to the 
severe immunological phenotype. In contrast to the immunosubunits β1i (LMP2) and β5i (LMP7), 
mutations in the gene encoding MECL-1 have not yet been assigned to human disorders. The TUB6 
mutant mouse line exemplifies the involvement of MECL-1 in immunopathogenesis and provides the 
first mouse model for primary immuno- and thymoproteasome-associated immunodeficiency that may 
also be relevant in humans.
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The 26S proteasome is the major non-lysosomal protease engaged in degradation of intracellular proteins. 
Beyond basic protein homeostasis, proteasomes have wide-spread functions such as control of signalling path-
ways via selective proteolysis1 and generation of peptides for major histocompatibility complex (MHC) class-I 
presentation2. The heart of each 26S proteasome is the 20S core particle (CP), consisting of seven different α- and 
seven different β-subunits, arranged in a cylindrical complex of four stacked rings following an α1–7β1–7β1–7α1–7 
stoichiometry. The proteolytically active sites reside in the β1-, β2-, and β5-subunits and are buried on the inner 
side of the protease. The principal proteasome structure and its assembly pathway are highly conserved among 
species from yeast to mammals3,4. However, contrary to yeast, which harbours only one proteasome (yCP), mam-
mals express three different types of CPs with distinct enzymatically active β-subunit compositions: the consti-
tutive proteasome (cCP: β1c, β2c and β5c), the immunoproteasome (iCP: β1i (also known as LMP2), β2i (also 
known as MECL-1) and β5i (also known as LMP7)) and the thymoproteasome (tCP: β1i, β2i and β5t)5. The iCP 
is predominantly produced in lymphocytes, but its expression can be induced also in non-immune tissues by 
the pro-inflammatory cytokine interferon (IFN)-γ6,7. The iCP generates the majority of MHC class-I antigens 
required for efficient immune surveillance and pathogen clearance by CD8+ T cells as proven by knockout (KO) 
mice lacking individual8–10 or all three catalytic immunosubunits11. Biogenesis of the tCP is restricted to cortical 
thymic epithelial cells (cTECs) and β5t KO studies demonstrated that this type of CP is vital for positive selection 
during the CD8+ T cell maturation process12,13. Besides the cCP, iCP and tCP, mixed-type CPs incorporating the 
subunits β1i, β2c and β5i or β1c, β2c and β5i were identified14–16.
Due to the essential functions of the proteasome, mutations in any of its components are associated with 
diverse human diseases such as diabetes, cancer and autoinflammation17,18. Most proteasome-associated auto-
inflammatory syndromes (PRAAS), also known as autoinflammation, lipodystrophy and dermatosis (ALDD, 
OMIM entry 256040), are linked to mutations in the PSMB8 gene, encoding the iCP subunit β5i19–22. However, 
amino acid exchanges in other proteasome subunits such as α7, β7 and β1i were identified as well23. Although 
the pathogenic mechanisms are not yet completely resolved, CP assembly and activity defects are found in these 
patients irrespective of the underlying mutations22,23.
Biogenesis of the eukaryotic CP is a well-organised and highly controlled process, involving several chaper-
ones24,25. It starts with the formation of the α-ring from the subunits α1- α7. The β-subunits subsequently use the 
heteroheptameric α-ring as a docking platform to assemble in a well-defined order resulting in an α1–7β1–7 pre-
cursor complex (half-CP). Dimerisation of two half-CPs finally triggers autocatalytic removal of the propeptides 
from the β-subunits to yield a mature proteasome26,27. One of the first β-subunits that associate with the α1–7 ring 
is β215,28. Its long C-terminal tail is essential for viability in yeast and human cells by recruiting and positioning 
the adjacent β3 subunit29. Therefore, the β2 appendage is highly conserved in structure and sequence among 
eukaryotic species as well as constitutive and immuno-β2-subunits4,26. Once the CP is assembled, its subunit com-
position is unchangeable; hence, intracellular levels of CP types have to be regulated by de novo proteasome syn-
thesis30. Nevertheless, how the incorporation of constitutive vs. alternative subunits is controlled is still unclear.
In a large-scale mouse N-ethyl-N-nitrosourea (ENU) mutagenesis and phenotypic screening approach, aimed 
at discovering mutant mouse lines with clinical phenotypes as models for human diseases31, we identified the 
single amino acid substitution G170W in the proteasome subunit MECL-1 to cause severe combined immu-
nodeficiency (SCID) and systemic autoinflammation. Yeast mutagenesis as well as X-ray crystallographic data 
suggest that expression of the mutant β2i subunit aborts the biogenesis of iCPs and tCPs and is lethal to immune 
cells, which ultimately manifests in lymphopenia. Altogether, the here described mutation links for the first time 
an autoinflammatory syndrome to the β2i subunit of iCP and tCP and serves as a first mouse model for human 
ALDD/PRAAS diseases.
Results
Heterozygous TUB6 mutants are characterised by a predominant T cell defect. For discovering 
novel genes or gene functions, mouse mutagenesis models have proven to be invaluable32. The powerful mutagen 
ENU induces genome-wide point mutations33, mirroring human single nucleotide variants causative for numer-
ous monogenic disorders. As part of the ENU mutagenesis program, we analysed within the Immunology module 
of the German Mouse Clinic peripheral blood of F1 offspring from ENU-treated mice to identify mutants with 
immunological defects31,34–36. The founder animal of mutant mouse line TUB6 was selected by the phenotype of 
significantly decreased proportions of CD4+ and CD8+ T cells in peripheral blood and an increase of the CD4/
CD8 ratio (Fig. 1a). Further breeding revealed this phenotype to fully penetrate in heterozygous TUB6 mutants. 
This allowed for a clear differentiation from wild type littermates; otherwise heterozygotes did not display any 
visually apparent physical abnormalities. Body weights and immunoglobulin subtypes IgM, IgA, IgG1, IgG2a, 
IgG2b, IgG3 were within the range of wild type littermates (Supplementary Fig. S1). B-, NK cells and granulocytes 
were slightly increased in relative proportions, but not in absolute numbers, showing that the increase is relative 
to the decrease of T cells (Supplementary Fig. S1).
To assess the immune competence of heterozygous TUB6 mutants, we evaluated the immune response to 
a sublethal dose of Listeria monocytogenes (L.m.). In the early phase of infection (day 3), bacterial burden in 
spleens and livers of heterozygous mutants did not differ significantly from infected controls (Fig. 1b). On days 
5–7 post infection (p.i.), however, all heterozygous mice failed to control the infection, became moribund and 
had to be euthanised due to ethical reasons, while all littermate controls showed good health conditions (Fig. 1c). 
On day 7 p.i., analysis of the euthanised heterozygotes showed failure to eliminate the pathogen. Considerable 
numbers of living bacteria were recoverable from mutant spleen tissue, whereas wild type mice showed efficient 
clearance (Fig. 1d). Since lack of L.m. clearance points towards a T cell defect, we investigated pathogen-specific 
T cell responses in these mice. In heterozygous TUB6 splenocytes, we could hardly detect any H-2Kd/LLO91–99+ 
CD8+ T cells (Fig. 1e). Congruently, CD8+ T cells from heterozygous TUB6 mice failed to produce IFN-γ in 
response to restimulation with LLO91–99 peptide, whereas a significant IFN-γ+ induction in CD8+ T cells from 
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wild type mice was observed (Fig. 1f). CD8+ T cells from heterozygous TUB6 mice, however, were not gener-
ally deficient in cytokine production, as demonstrated by the ability of T cells to produce IFN-γ in response to 
antigen-independent stimulation with phorbol 12-myristate 13-acetate (PMA) and ionomycin (Fig. 1f).
Figure 1. Phenotype of heterozygous TUB6 mutants characterised by numerical and functional T cell defect. 
(a) T cell frequencies in peripheral blood from heterozygous mutants and littermate controls shown as box plots 
(pooled data from different experiments, WT n = 40, het n = 71) and representative dot plots (upper panel, gated 
on living CD45+ cells), and CD4 versus CD8 profiles of T cells (lower panel, gated on living CD45+ CD3+ TCRβ+ 
cells). (b–f) Challenge of heterozygous TUB6 mutants with a low dose of 5000 colony forming units (CFU) (b) or 
1000 CFU (c–f) Listeria. (b,d) Bacterial loads in indicated organs from infected mice on day 3 (b) and day 7 (d) 
p.i. Points indicate individual mice. DL detection limit. (c) Survival of infected mice. ****P < 0.0001, Log-rank 
(Mantel-Cox) test. (e,f) Analysis of antigen-specific T cell response on day 7 p.i. Relative proportions of H-2Kd/
LLO91–99 multimer+ cells as percentages of total splenocytes (e) and IFN-γ expressing CD8+ T cells in response 
to stimulation with dimethyl sulfoxide (DMSO, negative control), peptide LLO91–99 or phorbol 12-myristate 
13-acetate (PMA) and ionomycin (f). For flow cytometry dot plots please refer to Supplementary Fig. S1.
www.nature.com/scientificreports/
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In summary, in heterozygous TUB6 mice a selective T cell defect was observed, with a substantially reduced 
T cell compartment at baseline conditions and failure of developing a protective antigen-specific T cell response 
to L.m. infection.
Homozygous mutant TUB6 mice have a reduced life span and severe combined immunode-
ficiency (SCID). Upon heterozygous intercross, about 25% of the offspring revealed a significantly smaller 
body size (Fig. 2a) and a moribund appearance by 6 to 12 weeks of age. Flow cytometric analysis of peripheral 
blood demonstrated that homozygous TUB6 mice were profoundly lymphopenic and displayed T− B− NK− SCID 
(Fig. 2b). Residual T cells were predominantly CD4+; CD8+ T cells comprised only 0.002% of all splenocytes 
(Supplementary Fig. S2). As predicted for lymphocyte deficiency, thymus and lymph nodes were not detecta-
ble, while spleens were devoid of lymphocytes and lacked the normal red and white pulp morphology (Fig. 2c). 
Consistent with the B cell deficiency, immunoglobulin levels were below the detection limit (data not shown).
Proportions as well as total numbers of granulocytes were immensely increased in peripheral blood from 
homozygous mutants (Fig. 2b). Microscopy of blood smears confirmed that most leukocytes represented neu-
trophil granulocytes (Supplementary Fig. S2). Granulocyte infiltrates in varying degrees were detected in liver, 
spleen and lungs, as shown by myeloperoxidase (MPO) staining of tissue sections (Fig. 2d). Furthermore, 
homozygous mutants developed a progressive skin disorder characterised by hyperkeratosis, alopecia, lack of 
adipose tissue, and infiltration of neutrophil granulocytes (Fig. 2e). The pro-inflammatory cytokines IL-1β, IL-6 
and TNF-α were strongly increased in plasma from homozygous mutants, while IFN-γ, -α and -β were increased 
only in some individual mice (Fig. 2f).
Taken together, homozygous TUB6 mice exhibit a lethal immunological phenotype comprising SCID and 
systemic inflammation.
T and NK cell deficiency is inborn, while B cell deficiency and granulocytosis develop later in a 
commensal-independent manner. In contrast to athymic adolescent homozygotes, vestigial thymi were 
present in new-born homozygotes, excluding a general thymus anlage defect. Despite the presence of a thymus, 
T cells were profoundly reduced in peripheral blood and spleens from homozygous TUB6 neonates (Fig. 3a). NK 
cells were also drastically decreased in the periphery, whereas B cell and granulocyte frequencies were comparable 
to wild type levels (Fig. 3a). Flow cytometric analysis of TUB6 homozygous neonatal thymi revealed decreased 
frequencies of CD4SP (single positive) and CD8SP thymocytes compared to control littermates (Fig. 3b), sug-
gesting arrest during thymocyte development at the double positive (DP) stage. Furthermore, flow cytometric 
analysis of thymic stroma cells revealed lack of cTECs in thymi from homozygous neonates (Fig. 3c).
We hypothesised that vanishing of the B cell- and simultaneous expansion of the granulocyte-compartment 
might be due to enhanced susceptibility to opportunistic infection(s) as a consequence of the inborn severe T and 
NK cell deficiency. To test this hypothesis, we evaluated the TUB6 mutant phenotype after transfer of the line into 
a germ-free environment. However, the disease developed identically under germ-free conditions, and germ-free 
heterozygous as well as homozygous TUB6 mice represented phenocopies of mutants with a conventional micro-
flora (Supplementary Fig. S3), including homozygous lethality. These findings indicate that the TUB6 phenotype 
results from sterile inflammation and develops independently of the microbiome.
Underlying genetic alteration identified as a point mutation in Psmb10, encoding MECL-1. In 
an initial mapping attempt to identify the chromosomal localisation of the underlying genetic mutation, we found 
a strong linkage with markers located on chromosome 8 (Supplementary Fig. S4). The strongest linkage (log-
arithm of the odds (LOD) >16) was detected with rs13479998 (8: 114,166 Mb, http://ensembl.org), although 
the mapping approach still left a large candidate region. Comparison of the TUB6 phenotype with existing 
gene-targeted mice and human inherited disorders failed to reduce the number of candidate genes.
The vast majority of ENU-induced genetic alterations are based on critical point mutations in coding regions 
or splice sites, therefore we utilised deep whole exome sequencing to identify the underlying TUB6 mutation37,38. 
We found only one homozygous point mutation present in analysed affected mice but not in the wild type con-
trols (Fig. 4a). This mutation was located exactly within the previously mapped candidate region.
The mutated gene Psmb10 encodes MECL-1, one of three catalytic subunits of the iCP and tCP. The identified 
point mutation leads to an amino acid exchange from glycine to tryptophan at the strictly conserved position 
170 (Fig. 4b). In order to validate the mutation, we analysed tail DNA samples from more than 500 inbred mice 
and found a phenotype-genotype correlation of 100%. Furthermore, we backcrossed the TUB6 mouse line onto 
C57BL/6 (F7) and BALB/c (F11) backgrounds and found strong phenotype persistence (Supplementary Fig. S4). 
When TUB6 mice were crossed to MECL-1 KO mice, the resulting hemizygous offspring (MECL-1−/G170W) pre-
sented all key features of the homozygous TUB6 phenotype, i.e. lack of T and NK cells and substantial lethality 
(leukocyte frequencies are shown in Supplementary Fig. S4). These findings demonstrate the causal relationship 
of the MECL-1G170W mutation and the severe TUB6 phenotype.
Overexpression of MECL-1G170W is lethal for murine cells. To assess the effect of MECL-1G170W on 
murine cells, we cloned the coding sequences of wild type MECL-1 and MECL-1G170W into the retroviral mP71 
vector. The generated constructs (Fig. 5a) were used to produce viral particles for transduction of primary wild 
type splenocytes. Due to the fact that retroviruses infect only proliferating cells, splenocytes were stimulated with 
agonistic anti-CD3 and anti-CD28 antibodies to induce T cell proliferation 24 h prior to transduction. Following 
retroviral transduction, two parallel culture conditions for splenocytes were applied: either prolonged stimula-
tion with anti-CD3 and anti-CD28 antibodies, or incubation with interleukin (IL)-2 and IL-15. The frequency 
of green fluorescent protein (GFP)+ cells decreased over time in cells transduced with MECL-1G170W (Fig. 5b), 
showing a lethal effect of MECL-1G170W overexpression even in presence of endogenous wild type MECL-1. 
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Furthermore, there was no evidence for stimulus-dependent effects. Both, the T cell receptor (TCR)-engaging 
CD3/CD28 and TCR-bypassing IL-2/IL15 stimulations lead to a similar decrease of MECL-1G170W-expressing 
cells (Fig. 5b). Annexin V staining 36 h post transduction revealed higher frequencies of apoptotic cells, showing 
an increase of programmed cell death in MECL-1G170W expressing cells (Fig. 5c). Taken together, these results 
Figure 2. Phenotypic comparison of 8-week-old homozygous TUB6 mutants and wild type littermates. (a) Body 
weight data (n = 8–10 per group). (b) Flow cytometric profile of peripheral blood leukocytes (pooled, hom n = 11, 
WT n = 44). The right box plot shows granulocyte counts after equal acquisition time per sample, normalised to 
the mean of wild types. For flow cytometry dot plots see Supplementary Fig. S2. (c–e) Representative (immuno-)
histological images of spleen (c), neck skin (e) and further indicated organs (d) stained with HE (c,e), anti-CD3 or 
anti-B220 (c) as indicated, or anti-MPO (d). (f) Cytokine concentration in plasma.
www.nature.com/scientificreports/
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Figure 3. Phenotype of neonatal TUB6 mutants. Flow cytometric analysis of indicated cell populations from 
2–5-day-old pups: splenocyte frequencies (a) and CD8SP and CD4SP thymocytes (b). a and b show pooled 
data from 3 litters analysed on 3 different days (n = 5 WT, 4 het, 4 hom). (c) Analysis of thymic stroma: cortical 
thymic epithelial cells (cTECs: Epcam+Ly51+) and medullary thymic epithelial cells (mTECs: Epcam+Ly51−), 
gated on CD45− cells (n = 2), shown as percentages of CD45− cells or as total cell counts. (a–c) For flow 
cytometry dot plots see Supplementary Fig. S3.
Figure 4. Underlying genetic alteration identified as missense point mutation in Psmb10 at a highly conserved 
position. (a) Sanger sequencing of the Psmb10 gene exon 7 shows the G > T nucleotide substitution leading 
to an amino acid exchange from Gly to Trp in TUB6 mice. (b) Multi-species alignment revealed the strict 
evolutionary conservation of glycine 170 (indicated by a red arrow). Amino acid numbers are assigned 
according to the sequence alignment to the β-subunit of Thermoplasma acidophilum.
www.nature.com/scientificreports/
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clearly demonstrate lethal effects of MECL-1G170W overexpression on murine splenocytes. Furthermore, MECL-
1G170W transduced T cells undergo rapid apoptosis independent of persistent TCR engagement.
G170W mutation in analogous yeast β2 subunit is lethal. Gly170 is located in a structurally highly 
conserved region of subunit β2 at the interface of the two proteasome β-rings in both the mouse iCP3 and the 
yCP39. Hence, its mutation to Trp was assumed to sterically hinder dimerisation of two half-CPs and to interfere 
with CP assembly. To prove this hypothesis, we conducted yeast mutagenesis experiments. Noteworthy, yeast 
expresses only one type of CP and any interruption of its assembly is lethal. We introduced the TUB6 point muta-
tion G170W into the LEU2-plasmid pRS315-PUP1, encoding the β2 subunit of the yCP. Transformation of the 
Figure 5. Overexpression of mutated MECL-1 causes cell death in murine splenocytes. (a) Schematic 
illustration of the GFP (green fluorescent protein) reporter constructs used for transduction. Fusion of MECL-1 
and GFP ensures co-expression of both proteins. To rule out fusion effects, two different linkers between 
MECL-1 and GFP were used: In the first setting the P2A self-cleavage motif hydrolyses the protein chain, 
resulting in two separate proteins. In the second setting the self-cleavage ability of P2A was abrogated by a 
mutation, leading to expression of one fused MECL-1 GFP protein. (b) Kinetics of the GFP signal detected in 
the splenocyte population after transduction. Plots show changes in GFP signal relative to transduction efficacy. 
After transduction, T cells were stimulated with anti-CD3 and anti-CD28 antibodies (left panel) or IL-2 and 
IL-15 (right panel). (c) Apoptotic cells identified by Annexin V staining 36 h after transduction are plotted as 
percentages of transduced (GFP+) cells. Data from one representative overexpression experiment are shown, in 
total the experiment was performed twice with similar results. In each experiment splenocytes were transduced 
with two different virus supernatants. Each point in the dot plots shows data from one separately transduced 
splenocyte sample.
www.nature.com/scientificreports/
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yeast strain YWH10 (pup1Δ::HIS3 [pRS316-PUP1]) with the constructed mutant (mt) plasmid and subsequent 
selection of transformants on 5-FOA plates for removal of the URA3-marked pRS316-plasmid encoding wild 
type (WT) PUP1 demonstrated that the pup1G170W mutant was not viable. Because expression of a proteolytically 
inactive pup1 variant (e.g. Thr1Ala) does not provoke any phenotype in yeast40,41 a general proteasome assembly 
defect was supposed to cause the lethality of pup1G170W (Fig. 6a).
In parallel, we performed the plasmid shuffling with a construct encoding Ala on the same position 170. Like 
pup1G170W, the pup1G170A mutation was lethal to yeast, yet viability could be restored by fusing a Protein A-His7-tag 
(ProA-H7) to the C-terminus of the mutant yβ2G170A subunit. Although the resulting pup1G170A-ProA-H7 mutant 
suffered from a pronounced growth defect (Fig. 6a), its viability was indicative of the successful incorporation 
of the mutant yβ2 subunit into yCPs. Notably, proteasome activity in the pup1G170A-ProA-H7 mutant cells was 
not impaired compared to wild type strains - a fact that might arise from proteasome subunit overexpression 
to overcome an assembly defect (Supplementary Fig. S5). In contrast to the pup1G170A mutant, a C-terminal 
ProA-His7-tag could not rescue the pup1G170W yeasts. These results suggest that the bulky tryptophan residue has 
additional negative effects on the proteasome assembly line compared to the smaller alanine.
Next, the mutant alleles were overexpressed in WT yeast, using a 2 µ plasmid. Consistent with the shuf-
fling experiments, we observed clearly reduced growth rates and colony sizes of the pup1G170A, pup1G170W and 
pup1G170W-ProA-H7 transformants compared to the controls and compared to the pup1G170A-ProA-H7 expressing 
yeasts (Fig. 6b). Although the ProA-H7 tag has a positive effect on the proliferation of WT yeasts that overexpress the 
G170A and G170W mutant alleles, this partial rescue is insufficient to overcome lethality of the pup1G170W-ProA-H7  
mutant during plasmid shuffling.
Proteasome assembly defects, as supposed for the pup1G170A(-ProA-H7) and pup1G170W(-ProA-H7) mutants, 
often lead to reduced proteasome activity because immature intermediates as well as inactive β subunits with 
propeptides attached (proproteins) accumulate. We therefore analysed lysates of pup1G170A-ProA-H7 mutant and 
PUP1-ProA-H7 wild type yeast cells by SDS- or native PAGE, followed by immunoblotting against either the 
His-tag or yβ7, the endmost subunit incorporated into half 20S proteasomes. These experiments clearly showed 
that yβ2-precursor subunits as well as half yCPs accumulate in the mutant (Fig. 6c and Supplementary Fig. S6).
In conclusion, mutation of yβ2-Gly170 severely disturbs the proteasome assembly line. Lethality of a G170A 
mutation can be rescued by a C-terminal ProA-H7-tag, but in agreement with the growth defect observed, pro-
teasome maturation is impaired and half CPs as well as unprocessed yβ2 subunits accumulate, suggesting that 
dimerisation of half CPs is sterically hindered in the pup1G170A-ProA-H7 mutant.
G170A mutation distorts the assembly-relevant C-terminal appendage of subunit β2. The 
pup1G170A-ProA-H7 mutant yCP was purified by affinity chromatography and crystallised after tag removal by 
Tobacco Etch Virus (TEV) protease (Supplementary Fig. S7). The structural data (Supplementary Table S1) 
visualised the incorporation of the point mutation G170A and verified correct autolysis of the yβ2-propeptide. 
Furthermore, a crystal structure in complex with the inhibitor bortezomib (Velcade®) displayed full occupancy of 
the ligand at each proteolytic centre, thereby confirming the functional integrity and reactivity of all proteasomal 
active sites (Supplementary Fig. S8). Owing to the purification procedure, which is based on activity assays to 
identify proteasome-containing fractions, only active particles but no assembly intermediates were isolated (see 
Materials and Methods).
The structural data visualise that WT and mutant yβ2-subunits superimpose well (WT/mt: r.m.s.d. 0.3 Å), 
except for the segment Pro192-Glu197. In the mutant structure this loop is strongly distorted and less well 
resolved in the 2FO-FC electron density map compared to the WT yβ2-subunit (Fig. 7a,b). Detailed inspection of 
the site of mutation reveals that Ala170 would be too close to Arg19 from the same subunit (3.0 Å) as well as to the 
C-terminal amino acid Asp190 from subunit yβ6′ of the opposite β-ring (2.6 Å; Fig. 7c). To avoid steric clashes, 
the guanidine group of Arg19 (yβ2) and the carboxylate of Asp190 (yβ6′) are shifted by up to 1.6 Å. Hereby, 
the hydrogen bonds between Arg19NH2 and Asp190OD2 (WT: 3.1 Å; mt: 5.1 Å) as well as Arg19NH2 and the 
C-terminus of subunit yβ6 (WT: 3.1 Å; mt: 4.5 Å) are broken. Furthermore, slight backbone distortions around 
the mutation shorten the distance between Ser171O and Pro192CD from 3.5 Å to 2.9 Å. This close contact leads 
to a flip of Pro192 out of the hydrophobic pocket provided by Ile163, Trp164, Val173 and Leu190 of yβ2 (Fig. 7c), 
however, without changing its trans conformation (Fig. 7d). The reorientation of Pro192 triggers twisting of the 
succeeding yβ2-amino acids Asn193-Glu196 outwards on the protein surface (shift of Pro192Cα: 1.6 Å; Asn193Cα: 
6.6 Å; Val194Cα: 5.7 Å; Arg195Cα: 4.8 Å; Glu196Cα: 2.0 Å; Glu197Cα: 0.6 Å; Fig. 7c), hereby loosening intra- and 
inter-subunit contacts. For instance, the hydrogen bridges between Asn193ND2 and Ser171O (WT: 3.0 Å; mt: 
9.6 Å) as well as Arg195NH2 and Glu139OE2 of yβ3 (WT: 3.0 Å; mt: 11.7 Å) are broken. All these structural 
changes affect the orientation of the C-terminal appendage of subunit β2, which is vital for eukaryotic half-CP 
assembly by governing the association with the neighbouring subunit β3 via β-sheet interactions28,38. Most likely, 
mutation of Gly170 enhances the structural flexibility of the C-terminal tail of yβ2 and impairs the association 
with subunit yβ3 of the same β-ring/CP half (cis interactions). The very C-terminus of subunit β2 approaches 
subunit α3 of the same CP half, suggesting that the ProA-tag facilitates cis interactions (within the same hemi-
proteasome) and thereby compensates for the deleterious conformational change in the yβ2-appendage. Besides, 
mutation of Gly170 appears to impair half-proteasome association for steric reasons (Fig. 6c).
Western blotting of spleen and thymus lysates from homozygous TUB6 mutants revealed an accumulation of 
the MECL-1G170W precursor and reduction of processed MECL-1G170W (Supplementary Fig. S9). Furthermore, in 
lysates of primary mouse embryonic fibroblasts derived from mutant TUB6 mice, a partial accumulation of the 
MECL-1 precursor was observed (Supplementary Fig. S9), supporting the conclusion that mutation of Gly170 in 
the proteasomal β2 subunit induces pronounced structural changes that impair proper particle assembly.
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Discussion
Here we describe for the first time the mutant mouse line TUB6 that carries the point mutation G170W in MECL-
1, the β2i subunit of the iCP and tCP. Heterozygous mutants are characterised by reduced numbers of T cells at 
baseline conditions and an impaired T cell response to Listeria challenge. While the early innate response to 
Listeria involving neutrophil granulocytes, NK cells, and macrophages is able to control the infection in the first 
3 days42, TUB6 mutants succumb later during the course of infection, when Listeria-specific IFN-γ-producing 
CD8+ effector T cells are indispensable for bacterial clearance43,44. However, PMA/ionomycin stimulation 
demonstrated that MECL-1+/G170W T cells are still capable of producing effector cytokines, ruling out a general T 
cell activation defect.
Figure 6. Yeast mutagenesis experiments. (a) Drop test of mutant yeast strains. Indicated cell numbers 
were spotted on YPD plates and incubated for 1–3 days either at 30 or 37 °C. Growth of the yeast β2 (pup1) 
G170A-ProA-H7 mutant is retarded compared to the respective wild type strains and compared to the β2 
loss of function mutant T1A. (b) Overexpression of mutant yeast β2-subunits. Wild type yeast (WCG4a) was 
transformed by either the empty 2 µ plasmid pRS425 or variants thereof encoding wild type PUP1 or mutant 
pup1 genes. Yeasts were streaked on CM Leu− plates (to select for the plasmid pRS425) and grown at 30 °C. (c) 
Western blot of equal amounts of β2 (pup1) G170A-ProA-H7 and β2 (PUP1)-ProA-H7 cell lysates separated by 
SDS-PAGE (upper panel) or native PAGE (lower panel). Anti-His immunoblotting of denatured lysates reveals 
that the mutant accumulates immature β2 (pro-β2), while in wild type cells the processed version of β2 is more 
abundant. In agreement, probing native lysates with an anti-β7 antibody visualises the accumulation of half 20S 
proteasomes in the mutant. Note, β7 is the last proteasome subunit that is incorporated into half proteasome 
precursors. Full-length western blots are presented in Supplementary Fig. S6.
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The homozygous TUB6 phenotype matches the main symptoms of the human diseases ALDD/PRAAS, 
i.e. autoinflammation, granulocyte infiltration into the skin, and lipodystrophy19–21,23. In addition, TUB6 mice 
develop B-T-NK-SCID, which was not reported in ALDD/PRAAS patients so far. MECL-1 is part of both the iCP 
and tCP. Deficiency for tCPs alters the positive selection of CD8+ T cells, thereby reducing CD8SP thymocytes 
and CD8+ T cells in the periphery, but not CD4SP thymocytes and CD4+ T cells12,13. The absence of CD4SP thy-
mocytes and peripheral CD4+ T cells in homozygous TUB6 mice compared to the β5t−/− KO might result from 
the complete lack of the tCP-expressing cTECs. This is supported by the finding that transient cTEC depletion 
Figure 7. Crystal structure of the yeast β2-G170A mutant proteasome. (a) Ribbon illustration of the G170A 
mutant yeast proteasome subunit β2 (brown) superimposed onto the wild type counterpart (grey) and the 
mouse iCP subunit β2i (black) on the left; association of the subunits β2 and β3 (purple) is shown on the right. 
The site of mutation and the resulting conformational changes in the β2 C-terminal tail are marked by red and 
black arrows, respectively. (b) Stereo representation of the 2FO-FC omit electron density maps for the G170A 
mutant (brownish) and wild type yβ2 subunit (grey) contoured to 1σ. Note the structural changes and the 
increased flexibility of the loop segment in the mutant structure. The flip of Pro192 is marked by a black arrow. 
(c) Hydrogen-bonding network around the site of mutation. Exchange of Gly170 in subunit yβ2 results in the 
reorientation of residues 192–196 (black arrows). Hereby hydrogen bonds (black dotted lines) within yβ2 and 
with the neighbouring subunits yβ3 and yβ6′ (of the opposite half proteasome) are broken. Steric clashes are 
marked by black double arrows. (d) The strictly conserved Pro192 is supposed to orient the β2 C-terminus 
for association with the adjacent β3 subunit. In the mutant crystal structure, flipping of Pro192 changes the 
conformation of the β2 C-terminus. Species abbreviation in sequence alignment: t: T. acidophilum; y: yeast; m: 
mouse; h: human; b: Bos taurus; c: Canis familiaris; r: Rattus norvegicus; s: Sus scrofa; amino acid numbers are 
assigned according to the β-subunit of T. acidophilum.
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leads to impaired development of both, CD4+ and CD8+ T cells45. Since other cell types such as NK- and B-cells 
are unaffected by cTEC depletion, additional factors are assumed to cause SCID in TUB6. The B cell loss in TUB6 
temporally correlates with granulocyte expansion and may be based on exposure and enhanced susceptibility to 
opportunistic infections. Accelerated granulocyte production in response to infection is known as “emergency 
granulopoiesis” and is accompanied by decreased lymphocyte production46. The TUB6 mutant, however, devel-
ops this disease also under germ-free breeding conditions, indicating establishment of SCID and sterile autoin-
flammation in the absence of microbial triggers.
In order to improve our understanding of the pathogenesis in TUB6, we were interested in elucidating its 
molecular basis. Mutagenesis experiments in yeast, expressing only one CP variant, revealed that any change of 
Gly170 in the yeast proteasome subunit yβ2, to either Trp or Ala, is lethal. Since inactivation of the yβ2 active 
site does not interfere with yeast viability40,41, the mutation of Gly170 was supposed to hamper CP biogenesis. 
Fortunately, fusion of a ProA-H7-tag to the yeast β2-C-terminus rescued the G170A mutant and enabled the 
structural analysis of its yCP. The X-ray crystallographic data visualise that the point mutation G170A leads to sig-
nificant rearrangements in a loop region of the C-terminal appendage of subunit yβ2. The C-terminal extension 
of β2 is pivotal for survival of yeast and mammalian cells, as it governs the incorporation of the adjacent subunit 
yβ328,29. The very C-terminal β-sheet, engaged in interactions with the neighbouring subunit yβ3 is unaffected in 
the mutant; however, the unusual arrangement of the yβ2 tail may interfere with yβ3 association and thus cause 
failure of the proteasome assembly line in the pup1G170A and pup1G170W mutants (Fig. 8). Presumably, fusion of the 
C-terminal ProA-H7-tag to yβ2 stabilises the interactions of yβ2 with yβ3 and with the α-ring, thereby supporting 
half-proteasome formation in the pup1G170A-ProA-H7 strain. Nonetheless, dimerisation of the half-CPs seems to 
be impaired (Fig. 6c). In contrast to the pup1G170A yeasts, the mutation G170W is lethal in the absence and pres-
ence of the ProA-H7-tag, implying that the bulky tryptophan either completely blocks β-ring assembly or prevents 
fusion of hemiproteasomes for steric reasons. Considering that the pup1G170A-ProA-H7 mutant accumulates half 
CPs (Fig. 6c), the latter hypothesis likely applies to the pup1G170W-ProA-H7 mutant (Fig. 8).
Notably, the severe immunological defect of the TUB6 mouse clearly contrasts the mild phenotypes of the 
reported KO mice lacking iCP or tCP subunits8,9,11–13, but our following model provides an explanation: In 
MECL-1 deficient mice the corresponding constitutive subunit β2c fills in for MECL-1 and thus, CP assem-
bly leads to either homogenous cCPs or mixed type CPs containing the subunits β2c, β1i, β5i or β2c, β1c, 
β5i14. Similarly, β5t KO mice are assumed to incorporate either β5c or β5i in their CPs as a mechanism of 
Figure 8. Model of CP assembly and proposed impact of the TUB6 mutation on iCP/tCP biogenesis. The 
mutations G170W and G170A in the yβ2 proteasome subunit abrogate assembly of the yeast CP (upper panel). 
Since the β2-G170A-Pro-H7 mutant accumulates half CPs (Fig. 6c), the β2-G170W-Pro-H7 mutant is likely to 
suffer from a defect concerning half CP dimerisation. Similarly, the TUB6 mutation G170W in the proteasome 
subunit β2i leads to a major arrest in precursor complex processing and an inefficient, minor progression to 
mature iCP/tCP (lower panel). Colour code: β1 (green), β2 (brown), β3 (violet), β5 (olive).
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compensation47 and iCP triple KO mice can at least assemble CPs containing β2c, β1c, β5c as well as β2c, β1c, β5t 
in the absence of the immunosubunits. Furthermore, due to the availability of subunit β5c, also β5t−/− β5i−/− mice 
do not suffer from a phenotype comparable to the TUB6 mouse13. All these KO mice still can form at least one 
type of functional CP that ensures cell survival, thus the resulting phenotypes are modest and manifest in antigen 
presentation defects leading to reduced CD8+ T cell repertoires8,11,13.
By contrast, the mutant MECL-1G170W cannot be substituted by its constitutive counterpart β2c, because in 
cells expressing immuno- and constitutive subunits association of the heptameric α-ring with MECL-1 and β1i 
is preferred over β2c incorporation48 (Fig. 8). Our structural data on the β2-G170A mutant yCP suggest that 
the mutation G170W in MECL-1 does not alter the interactions with the α-ring, but may prevent or destabilise 
the association with subunit β3, thereby leading to the formation of dead-end CP intermediates, containing the 
α-ring, β1i and MECL-1G170W.
In agreement, our data show that overexpression of MECL-1G170W is lethal for murine T cells and that the 
immature MECL-1 precursor is found in the thymus and the spleen of homozygous TUB6 mutants. The failure 
to produce enough functional CP in MECL-1G170W-expressing cells ultimately results in their massive demise and 
immunodeficiency. Cell death is a potent trigger of sterile inflammation marked by neutrophil recruitment49. 
Thus, this model also explains the observed granulocytosis and neutrophil infiltration into tissues.
Reminiscent of the TUB6 mouse, substantial loss of cTECs and thymic tissue was recently reported for a 
Gly170Arg missense mutation in Psmb11, the gene encoding the tCP-specific subunit β5t50. Interestingly, subunit 
β5t features an extended C-terminus similar to β2 subunits, which is absent in β5c and β5i12. The β5tG170R mutant 
subunit was found to be immature, to induce the accumulation of tCP precursor complexes, and to trigger cell 
death in β5t-expressing cells50. Due to the lack of any structural information on the tCP, it still remains to be 
elucidated which of the β subunits fails to interact with the mutant β5t subunit. The distinct phenotypes of the 
β5t and β2i missense mutations versus the respective KOs, however, demonstrate the power of phenotype-driven 
“forward genetics” to identify a broader range of gene functions than with the “reverse” gene-driven approach51. 
Besides the insights into basic proteasome biology, TUB6 provides the first mouse model for human ALDD/
PRAAS syndromes. Although for human PRAAS a global proteasome dysfunction is suggested, rather than 
specific immunoproteasome dysfunction23, the TUB6 phenotype is associated to defects in immuno- and/or 
thymoproteasome biology, particularly regarding the early T cell loss in new-born homozygotes and also the 
heterozygous T cell-specific phenotype.
Given the high structural and functional homology of the murine and human MECL-1, and the severe infec-
tion susceptibility phenotype in heterozygotes, our data suggest to include MECL-1 as a candidate gene for 
screening in human individuals with primary immunodeficiency of unknown aetiology.
Methods
General statistical evaluation. Box plots indicate the median, the first and third quartiles, and the min-
imum and maximum values. Statistical differences between groups were determined by the Mann-Whitney 
rank-sum using Prism v.6 (GraphPad Software, Inc., La Jolla, CA). Asterisks indicate P values *<0.05, **<0.01, 
***<0.001, ****<0.0001.
Mice. All mouse experiments were approved by the Regierung of Oberbayern and all methods were carried 
out in accordance with the approved guidelines.
The TUB6 mutation was generated on the inbred C3HeB/FeJ strain purchased originally from the 
Jackson Laboratory (Bar Harbor, ME, USA) in a large-scale ENU mouse mutagenesis program as previously 
described31,52,53. Mice were housed under specific pathogen-free conditions at the mouse facility at the German 
Mouse Clinic.
Mice were originally tentatively grouped into wild type, heterozygous and homozygous groups according to 
their phenotype. Genotyping was performed retrospectively after the mutation was found.
For generation of germ-free TUB6 mice, 4–6-week-old heterozygous TUB6 females were superovulated 
by intraperitoneal (i.p.) injection of 7.5 international unit (IU) pregnant mare serum gonadotropin (PMSG), 
and 4 h later 7.5 IU human chorionic gonadotropin (hCG), and on the same evening paired with heterozygous 
TUB6 males. On the following morning, successful mating was controlled by plug check; plug positive females 
were shipped to Clean Mouse Facility (CMF), University of Bern (Bern, Switzerland). Upon arrival, the females 
were euthanised and the transfer of two-cell embryos into pseudopregnant female recipients was performed as 
described previously54.
Infection. Infection experiments were performed with the wild type L.m. strain 10403s. Brain heart infusion 
(BHI) medium was inoculated with Listeria stock solution and incubated at 37 °C until an OD600 of 0.05–0.1. 
After dilution with phosphate-buffered saline (PBS) to an appropriate concentration the infection of mice was 
performed with the indicated dose by i.v. injection into the lateral tail vein.
To estimate bacterial burden of organs, on the indicated time-point after infection mice were sacrificed. 
Spleens and livers were homogenised in the gentleMACS™ dissociator (Miltenyi Biotec Inc., Bergisch Gladbach, 
Germany) according to manufacturer’s recommendation. Serial dilution triplicates of Triton-lysed organ 
homogenates (ranging from 1:10 to 1:1000) were plated on BHI agar plates. After an overnight incubation at 
37 °C, colony forming units (CFU) were quantified by counting colonies.
Sample preparation and flow cytometry. Spleens or thymi were homogenised in the gentleMACS™ 
dissociator according to manufacturer’s recommendation. Peripheral blood from isoflurane-anesthetised mice 
was obtained by puncture of the retro-orbital sinus.
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Cells were incubated with anti-CD16/32 (2.4G2; BD Biosciences, San Diego, CA, USA) in fluorescence- 
activated cell sorter (FACS) buffer (PBS, 0.5% bovine serum albumin (BSA), and 0.02% sodium azide, pH 7.45) 
followed by staining with a combination of fluorescence-conjugated antibodies targeting CD45 (30-F11), CD11b 
(M1/70), Gr-1 (RB6-8C5), CD19 (1D3), NKp46 (29A1.4), CD3 (17A2), CD4 (RM4-5), CD8 (5H10), CD5 (53–
7.3), TCRβ (H57-597), Ep-CAM (G8.8), Ly-51 (6C3), (BioLegend, San Diego, CA, USA; eBioscience, Frankfurt, 
Germany; BD Biosciences).
MHC multimer reagents for detection of CD8+ T cells specific for the immunodominant epitope in BALB/c 
mice (H-2Kd-restricted LLO91–99 peptide) were generated as described44. For live/dead discrimination, cells were 
incubated with ethidium monazide (EMA; Molecular Probes, Eugene, OR, USA) followed by MHC multimer and 
surface marker staining.
For intracellular cytokine staining, splenocytes were restimulated for 5 h at 37 °C with LLO91–99 (GYKDGNEYI) 
or with 0.5 μmol/L PMA and 0.25 μg ionomycin, or kept without stimulation (negative control with dimethyl 
sulfoxide (DMSO), Sigma-Aldrich, Inc., St. Louis, MO, USA) in the presence of Brefeldin A (Golgi Plug, BD 
Biosciences). Subsequently, cells were incubated with anti-CD16/32, followed by surface staining as described 
above. After fixation and permeabilization using the Cytofix/Cytoperm kit (BD Biosciences) according to 
the manufacturer’s recommendation, intracellular staining with anti-IFN-γ (XMG1.2, BD Biosciences) was 
performed.
Data were acquired on a Gallios flow cytometer (Beckman Coulter Inc., Brea, CA, USA) and further analysed 
with FLOWJO (Tree Star Inc., Ashland, OR, USA) software.
Flow cytometric analysis of transduced cells was performed as follows: one day after transduction, initial 
transduction efficacies were assessed by measurement of GFP producing cells. GFP expression was analysed 
over time as a surrogate marker for MECL-1WT or MECL-1G170W expressing cells. Annexin V staining was per-
formed 36 h after transduction using Pacific Blue™ Annexin V/SYTOX® AADvanced™ Apoptosis Kit (Thermo 
Scientific, Braunschweig, Germany).
Analysis of mouse plasma. Plasma samples were stored at −80 °C. Plasma concentrations of immunoglob-
ulins were determined in a bead array-based multiplex assay (Luminex xMAP Technology; Bio-Rad, Munich, 
Germany), which allows the simultaneous analysis of IgG1, IgG2a, IgG2b, IgG3, IgA, and IgM. The level of each 
isotype was calculated over a standard curve fitted with Four-Parameter-Logistic regression (Bio-Plex manager 
software, Bio-Rad).
For determination of TNF-α, IFN-γ, IL-1β, and IL-6 concentrations, the commercial MSD Proinflammatory 
Panel 1 (mouse) Kit was used according to the manufacturer’s instructions. Data were acquired and analysed 
using the MSD instrument (Meso QuickPlex SQ120, Meso Scale Discovery, Rockville, MD, USA) and the 
included MSD discovery workbench software. IFN-α and IFN-β2 plasma concentrations were assessed using 
2-Plex Mouse Procarta Panel (Thermo Scientific) according to the manufacturer’s instructions. Data were 
acquired and analysed on the iQue screener PLUS (Intellicyt, Albuquerque, NM, USA)
Histology and immunohistochemistry. Immersion-fixed (neutral buffered formalin, 4%) organs were 
embedded in paraffin using a Vacuum infiltration processor (Sakura TissueTEK model VIP 5E-F2, Tokyo, Japan) 
and sliced with a HM 335S Rotary Microtome (Thermo Scientific) to a thickness of 4 µm for HE stain or 1 µm for 
immunohistochemistry. Histological slides were dehydrated in decreasing ethanol series and rinsed in tap water.
For HE staining, slides were incubated for 2 min in Mayers’ acid Hemalum (BioOptica, Milano, Italy), fol-
lowed by bluing in tap water and immersion in EosinY (BioOptica) for 1 min. Stained slides were dehydrated with 
increasing ethanol series, mounted with Pertex® (Medite GmbH, Burgdorf, Germany) and coverslipped (Menzel 
Glaeser®, Braunschweig, Germany).
For immunohistological stainings, antigen retrieval was performed by heat induction (0.1 M EDTA 
pH 8.0, 25 min at 96 °C/0.1 M citrate pH 6.0 10 min/100 °C under pressure) or Proteinase K incubation 
(Roche, Basel, Switzerland, diluted 1:200, 8 min, RT). For blocking of unspecific bindings, 5% goat (Gibco, 
Carlsbad, CA, USA) or rabbit (Gibco) serum was used for 1 h followed by incubation with primary antibod-
ies targeting CD3 (DakoCytomation™, DAKO™, Glostrup, Denmark), B220 (BD Biosciences) or MPO 
(NeoMarkers, Fremont, CA, USA) at 1:100 dilution overnight at 4 °C. Slides were incubated with biotin con-
jugated secondary antibodies (α-goat-Biotin, Vector Laboratories, Inc., Burlingame, CA, USA, diluted 
1:200 or α-rabbit-Biotin, Vector Laboratories, Inc., diluted 1:750) for 1 h at RT. Detection was performed by 
incubation with streptavidin-peroxidase (SS HRP Label, BioGenex, Fremont, CA) for 15 min and subse-
quently 3,3′-diaminobenzidine (DAB, DCS Innovative Diagnostic Systems, Hamburg, Germany) for 3 min. 
Counterstaining was performed using Mayers’ acid hemalum for 10 sec followed by bluing in tap water. 
Dehydration and mounting was performed as described above.
Genetic mapping. Heterozygous TUB6 animals were backcrossed twice with C57BL/6 J mice and the result-
ing offspring interbred to produce homozygous TUB6 mutants with clearly detectable phenotype. We analysed 
DNA from 44 phenotypically homozygous TUB6 mutants using 137 single nucleotide polymorphism (SNP) 
markers55. For each marker analysed, the LOD score was determined.
Capture, exome sequencing, variant calling. We performed in-solution targeted enrichment of exonic 
sequences from two homozygous TUB6 mice and one wild type littermate control using the SureSelectXT Mouse 
All Exon 50 Mb kit (Agilent Technologies, Santa Clara, CA, USA). The generated libraries were indexed, pooled 
and sequenced as 100 bp paired-end runs on a HiSeq2000 system (Illumina, San Diego, CA, USA).
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Read alignment to the mouse genome assembly mm9 was done with Burrows-Wheeler Aligner (BWA, version 
0.6.1) and yielded 10.6 Gb, 9.1 Gb and 8.3 Gb of mapped sequence data corresponding to an average coverage of 
109×, 103× and 76× for the two mutants and the wild type mouse, respectively. Single nucleotide variant (SNV) 
and small insertion and deletions (indel) detection with SAMtools (version 0.1.18) yielded 14,278, 14,256 and 
14,254 good quality non-synonymous coding variants. After filtering for homozygous variants present in the two 
TUB6 mice but not in the wild type mouse and 145 control mice with unrelated phenotypes, a single missense 
variant in the gene Psmb10 remained.
Cloning of proteasome mutants. The PUP1-TEV-ProA-His7 cassette56 including 503 bps of the endog-
enous PUP1 promoter and 229 bps of the tADH1 terminator was amplified from genomic DNA isolated from 
the yeast strain W303-PUP1-TEV-ProA-His7 (M. Groll, unpublished results) using the primers Pup1_for 
and Pup1_rev. The XbaI and HindIII digested PCR (polymerase chain reaction) product was inserted into 
the vector pRS315, carrying the LEU2 selection marker, to create pRS315-PUP1-TEV-ProA-His7. Point 
mutants were created by QuikChange site-directed mutagenesis using either the plasmid pRS315-PUP140 or 
pRS315-PUP1-TEV-ProA-His7 as template DNA. Introduction of point mutations was confirmed by sequenc-
ing. The mutant pRS315-pup1-TEV-ProA-His7 and pRS315-pup1 plasmids were introduced into the yeast strain 
YWH10 pup1Δ::HIS3 [pRS316-PUP1]41, which is chromosomally deleted for the PUP1 gene and instead carries 
a URA3-PUP1-episome. After growth on synthetic complete medium without leucine (CM leu−) transformants 
were selected on 5-fluoroorotic acid (5-FOA) for loss of the wild type URA3-PUP1-plasmid. Hereby, only yeasts 
encoding a mutant but functional pup1 gene can survive. Oligonucleotides, plasmids and yeast strains are listed 
in the Tables S2–S4.
Yeast drop test. Yeast strains were grown over night at 30 °C in liquid yeast extract peptone dextrose (YPD) 
medium. Serial dilutions of cells were spotted on YPD plates. Growth of the strains was evaluated after 1 and 3 
days at 30 °C and 37 °C.
Proteasome purification. Mutant yeast strains were grown in 18 l cultures at 30 °C in YPD into early sta-
tionary phase. Cells were resuspended in 100 mM Tris/HCl pH 7.5, 500 mM NaCl, 20 mM imidazole and dis-
rupted by French Press. Cellular debris was pelleted by centrifugation for 30 min at 41,000 g and the cleared 
cellular extract was loaded onto a Ni2+-NTA chromatography column. The proteasome was eluted by applying 
a linear gradient to 500 mM imidazole. The eluted protein fractions were immediately diluted in 100 mM Tris/
HCl pH 7.5 and 20% (v/v) glycerol in a 1:1 ratio, dialyzed against 20 mM Tris/HCl pH 7.5 and 50 mM NaCl 
and loaded onto an anion exchange chromatography column. To identify proteasome-containing fractions, 
protein samples were tested for their proteolytic activity against the fluorogenic substrate Suc-LLVY-AMC 
(N-Succinyl-Leu-Leu-Val-Tyr-7-Amino-4-methylcoumarin). Active fractions were pooled and subjected to size 
exclusion chromatography (Superose 6 10/300; 20 mM Tris/HCl pH 7.5, 100 mM NaCl). After incubation with 
TEV protease in a molar ratio of 1:100 for 15 h at 4 °C to remove the ProteinA-H7-tag, the samples were concen-
trated with a 100 kDa cut-off filter. This procedure separated the mutant proteasome from the TEV protease and 
the cleaved tag and allowed buffer exchange to 10 mM 2-(N-morpholino)ethanesulfonic acid (MES) pH 6.8.
Crystallisation and structure determination. Crystals were grown by the hanging drop vapour diffu-
sion technique at 20 °C. Protein (33 mg/ml) and reservoir solutions (100 mM MES pH 6.8, 20 mM magnesium 
acetate pH 6.8, 13 (v/v)% 2-methyl-2,4-pentanediol (MPD)) were mixed in a 2:1 ratio. Crystals were cryopro-
tected with 5 µl 100 mM MES pH 6.8, 20 mM magnesium acetate pH 6.8, 30% (v/v) MDP and either vitrified in 
liquid nitrogen immediately or after soaking with bortezomib for 24 h in a final concentration of 1.5 mM.
Diffraction data were collected using synchrotron radiation of λ = 1.0 Å at the beamline X06SA, Swiss Light 
Source (SLS), Villigen, Switzerland. X-ray intensities were analysed with the program package XDS57. The yeast 
wild type proteasome structure (PDB ID 5CZ4)58 served as a search model for structure determination by molec-
ular replacement with PHASER59. Cyclic refinement and model building were conducted with REFMAC560 and 
COOT61. TLS (translation/libration/screw) refinements with restraints between bonded and non-crystallographic 
symmetry-related atoms finally yielded excellent values for Rcrys, Rfree, r.m.s.d. bond and angle values as well as 
good stereochemistry from the Ramachandran Plot (Table S1).
Overexpression experiments. For overexpression experiments in yeast, pup1 gene versions were cloned 
from the pRS315 plasmids into the LEU2-marked high copy 2 µ plasmid pRS42562 using the restriction endonu-
cleases HindIII and SacI. Correct plasmids were transformed into the wild type yeast strain WCG4a and trans-
formants were selected on synthetic CM leu− plates.
For overexpression experiments in murine cells, spleen mRNA from a heterozygous TUB6 mouse was iso-
lated using TriReagent (Sigma-Aldrich) and transcribed to cDNA using Affinity Script Multiple Temperature 
cDNA synthesis kit (Agilent, Santa Clara, CA, USA). MECL-1WT and MECL-1G170W cDNA was amplified and 
linked to P2A GFP using an overlap extension method. MECL-1WT-P2A-GFP and MECL-1G170W-P2A-GFP were 
subsequently cloned into the mP71 retroviral expression vector. Platinum E cells cultured in DMEM medium 
(Thermo Scientific) supplemented with 10% FCS (fetal calf serum), 0.025% L-glutamine, 0.1% HEPES (4-(2-hyd
roxyethyl)-1-piperazineethanesulfonic acid), 0.001% gentamycin and 0.002% streptomycin were transiently 
transfected with the MECL-1WT-P2A-GFP and MECL-1G170W-P2A-GFP constructs using a calcium phosphate 
precipitation based method. Virus supernatant was harvested after 48 h. Subsequently a second virus superna-
tant was produced for 24 h in RPMI 1640 medium (Thermo Scientific) supplemented with 10% FCS, 0.025% 
L-glutamine, 0.1% HEPES, 0.001% gentamycin and 0.002% streptomycin. 24-well plates were coated with ret-
ronectin (6.25 µg/ml, Takara Bio Europe S.A.S., Saint-Germain-en-Laye, France), anti-CD3e (0.5 µg/ml, BD 
Biosciences, Clone 145.2C11) and anti-CD28 (0.1 µg/ml, BD Biosciences, Clone 37.51) diluted in PBS at 4 °C 
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overnight. Splenocytes were cultured in supplemented RPMI 1640 containing anti-CD3e (0.5 µg/ml), anti-CD28 
(0.1 µg/ml) and human IL-2 (20 U/ml, Proleukin® S, Novartis, Basel, Switzerland) for 24 h prior to transduc-
tion. On the day of transduction, diluted retronectin was removed and plates were coated with DMEM virus 
supernatant by centrifugation with 3000 g at 4 °C. DMEM virus supernatant was removed and splenocytes were 
resuspended in RPMI virus supernatant supplemented with human IL-2 (25 U/ml). Spinoculation was performed 
at 800 g, 32 °C for 1.5 h. Transduced T cells were subsequently cultured in supplemented RPMI 1640 with 25 ng/
ml human IL-15 (PeproTech Germany, Hamburg, Germany) and 25 U/ml human IL-2 or left in the anti-CD3e, 
anti-CD28 coated plates replacing the medium every two days with fresh medium containing 25 U/ml human 
IL-2.
Yeast cell lysate preparation. Yeast strains were grown in YPD medium at 30 °C and harvested during 
log-phase growth (OD600 1–2).
Native yeast cell lysates were prepared by resuspending 3·108 cells in 100 µl lysis buffer (50 mM Tris/HCl pH 
8.0, 5 mM MgCl2, 0.5 mM EDTA, pH 8.0, 1 mM ATP, AEBSF)62. Upon vortexing with acid washed glass beads 
(Sigma-Aldrich, 0.5 mm) for 5 × 1 min (with incubations on ice in between), the lysate was cleared by centrifuga-
tion (30 min, 15,000 g, 4 °C). The resulting supernatant was used for native gel analysis.
Denatured yeast protein extracts were prepared by dissolving 108 cells in 80 µl SDS-loading buffer (freshly 
supplemented with β-mercaptoethanol). The cells were shortly vortexed, boiled for 20 min at 95 °C and afterwards 
subjected to SDS-PAGE analysis.
Polyacrylamide gel electrophoresis and immunoblotting of yeast lysates. Native yeast lysates 
were mixed in a 1:1 ratio with native sample buffer (62.5 mM Tris-HCl pH 6.8, 40% (v/v) glycerol, 0.01% (w/v) 
bromophenol blue) and loaded on 4–15% gradient native gels (Mini-PROTEAN TGX Precast Gels, Biorad). 
Native gels were run for 3 h at 25 mA and 4 °C in native electrophoresis buffer (25 mM Tris, 192 mM glycine).
15% SDS gels were run for 40 min at 25 mA and 20 °C in standard electrophoresis buffer (25 mM Tris, 192 mM 
glycine, 0.1% (w/v) SDS). To distinguish between mature and immature yβ2 subunits, gels were run up to 2 h until 
the marker bands between 32 and 80 kDa (NEB, Color Prestained Protein Standard Broad Range) were properly 
resolved.
Prior to blotting, native gels were incubated for 20 min in transfer buffer63 containing 2.4% (w/v) SDS. 
Semi-dry blotting of native gels onto nitrocellulose membranes was performed for 3 h at 80 mA and 20 °C using 
transfer buffer. Afterwards, the membrane was incubated in 25 mM NaOH for 30 min and boiled for a few min-
utes. Blocking was performed for 1 h at 20 °C with 5% (w/v) milk powder dissolved in TBS (Tris-buffered saline) 
supplemented with 0.5% (v/v) Tween20 (T). Anti-β7 serum41 was applied in a 1:2,500 dilution in TBS-T (0.5% 
(v/v)) for at least 1 h at 20 °C. An anti-rabbit horseradish peroxidase (HRP) conjugate (A16110, Thermo Scientific) 
served as secondary antibody (1:10,000 dilution in 5% (w/v) milk TBS-T (0.1% (v/v))).
SDS gels were transferred onto nitrocellulose membranes for 1 h at 100 mA. The membrane was blocked for 
1 h at 20 °C with 5% (w/v) BSA dissolved in TBS supplemented with 0.1% (v/v) Tween20. The anti-His antibody 
(#2365, Cell signalling) was diluted 1:3,000 in 5% (w/v) BSA in TBS-T (0.1% (v/v)) and applied overnight at 4 °C. 
The secondary antibody, an anti-rabbit HRP conjugate (A16110, Thermo Scientific) was used in a 1:10,000 dilu-
tion in 5% (w/v) BSA TBS-T (0.1% (v/v)).
Upon enhanced chemiluminescence (ECL) development using Western Bright ECL-Spray (Advansta, Menlo 
Park, CA, USA) chemoluminescence was recorded by the ImageQuant LAS4000 biomolecular imager (GE 
Healthcare, Chalfont St Giles, UK).
Cleavage of the ProA-H7 tag by TEV protease was proven by anti-ProA western blotting. Upon blocking with 
5% (w/v) milk powder in TBS-T (0.1% (v/v)), anti-Protein A antibody (ABIN223591, Antikörper-online) was 
added to the blocking solution in a 1:2,000 dilution. The secondary antibody, an anti-rabbit alkaline phosphatase 
conjugate (A3687, Sigma-Aldrich) was applied in a 1:10,000 dilution in 5% (w/v) milk powder-TBS-T (0.1% 
(v/v)). Upon washing with TBS, colorimetric detection was started by the addition of NBT (Nitro blue tetra-
zolium chloride; 0.3 mg/ml) and 5-Bromo-4-chloro-3-indolyl phosphate (BCIP; 0.16 mg/ml) in buffer containing 
100 mM Tris/HCl pH 9.6, 100 mM NaCl and 5 mM MgCl2.
SDS-PAGE and western blot of murine organs. Mouse organs were lysed (10 mM Tris HCl pH 7.8, 
150 mM NaCl, 1% Triton X-100 and Complete Protease Inhibitor Cocktail (Roche)) on ice for 20 min. Lysates 
were centrifuged at 20,000 g and 4 °C for 15 min. Supernatants were mixed with SDS sample buffer and boiled 
for 5 min at 95 °C. Proteins were separated by SDS-PAGE (15% gel) and blotted onto nitrocellulose membrane 
(Whatman). Membranes were blocked for 1 h (5% milk powder/0.2% Tween20) followed by overnight incubation 
in primary antibodies (α-MECL-164 or α-iota (clone IB5, recognises the α1-subunit iota of the proteasome and 
was obtained from Prof. Dr. Klaus Scherrer (Institut JacquesMonod, Paris, France))) at 4 °C. Membranes were 
washed and incubated for 2 h with appropriate peroxidase-conjugated secondary antibodies (Dako). Membranes 
were washed and proteins were visualised with ECL.
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